

Performance report | 31 August 2024

Bennelong Concentrated Australian Equities Fund

Net returns

| | 1 mth | 3 mths | CYTD | 1 year | 3 years p.a. | 5 years p.a. | 10 years p.a. | Since inception ² p.a. |
|------------------------|--------|--------|--------|--------|--------------|--------------|---------------|-----------------------------------|
| Fund | 1.22% | 7.39% | 5.38% | 9.43% | -5.16% | 6.66% | 10.73% | 13.17% |
| Benchmark ¹ | 0.44% | 5.55% | 8.95% | 14.65% | 6.37% | 8.05% | 7.99% | 9.94% |
| Value added | +0.78% | +1.84% | -3.56% | -5.22% | -11.52% | -1.39% | +2.74% | +3.23% |

Performance figures are net of fees and expenses. 'Value added' calculation does not use rounded performance figures. Past performance is not indicative of future performance.

About the Fund

The Bennelong Concentrated Australian Equities Fund is a portfolio of BAEP's best high-conviction picks. It aims to grow investment value over the long term via a combination of capital growth and income, by investing in a diversified portfolio of Australian securities.

The Fund typically holds 20-35 securities across the spectrum of the Australian share market (primarily from the S&P/ASX 300 Accumulation Index).

Benefits of the Fund

- Concentrated into the team's best stock ideas from throughout the market
- Track record of adding value by outperforming the market over the long term
- Managed in accordance with BAEP's robust, disciplined and proven investment philosophy and process

About BAEP

Bennelong Australian Equity Partners (BAEP) is a boutique fund manager investing in Australian listed equities. It was founded in 2008 by Mark East, in partnership with Bennelong Funds Management.

BAEP is a genuinely active, award-winning and highly-rated fund manager with an experienced and performance-oriented team. Its investment philosophy is to selectively invest in high quality companies with strong growth outlooks and underestimated earnings momentum and prospects. Its investment process is research-intensive, with a focus on proprietary field research, and is supported by macro-economic and quantitative insights.

Portfolio sector allocation

| Sector | Fund Weight | Benchmark ¹ Weight | Active Weight |
|------------------|-------------|-------------------------------|---------------|
| Discretionary | 37.2% | 7.7% | 29.5% |
| Health Care | 25.8% | 10.0% | 15.8% |
| Communication | 9.5% | 3.8% | 5.8% |
| Liquidity | 0.1% | 0.0% | 0.1% |
| REIT's | 5.8% | 6.8% | -1.0% |
| Utilities | 0.0% | 1.4% | -1.4% |
| Consumer Staples | 2.7% | 4.1% | -1.4% |
| IT | 1.4% | 3.1% | -1.7% |
| Energy | 0.0% | 4.2% | -4.2% |
| Industrials | 2.9% | 7.1% | -4.3% |
| Materials | 7.5% | 19.6% | -12.1% |
| Financials | 7.1% | 32.2% | -25.0% |


Portfolio characteristics

| | Fund | Benchmark ¹ | Profile |
|------------------|-------|------------------------|----------------------|
| Return on Equity | 14.8% | 12.0% | Premium Quality |
| Debt/Equity | 11.2% | 38.2% | |
| Sales Growth | 6.9% | 3.1% | Superior Growth |
| EPS Growth | 11.7% | 3.4% | |
| Price/Earnings | 29.4x | 18.1x | Reasonable Valuation |
| Dividend Yield | 1.3% | 3.6% | |
| Beta | 1.19 | 1 | |
| Active Share | 84% | na | Genuinely Active |
| No. of Stocks | 24 | 292 | |

Source: broker consensus estimates for the next 12 months

Long-term performance

Growth of \$10,000 since inception^{2,3}



Top five active holdings

At month end, in alphabetical order

| Company |
|-----------------------------|
| ARB Corporation Limited |
| Breville Group Limited |
| CSL Limited |
| Fisher & Paykel Healthcare |
| James Hardie Industries PLC |

Top three contributors

To monthly relative performance, in alphabetical order

| Company | Avg active position |
|----------------------------|---------------------|
| Breville Group Limited | Overweight |
| Fisher & Paykel Healthcare | Overweight |
| Universal Stores | Overweight |

Top three detractors

To monthly relative performance, in alphabetical order

| Company | Avg active position |
|---------------------|---------------------|
| Cochlear | Overweight |
| Credit Corp | Overweight |
| The A2 Milk Company | Overweight |

The Fund at a glance

| Feature | Fund facts |
|--|--|
| APIR code | BFL0002AU |
| Benchmark | S&P/ASX 300 Accumulation Index |
| Investment objective | 4% p.a. above benchmark measured over rolling 3-year periods |
| Active stock limit | ± 10% |
| Cash limit | 0 - 10% |
| Inception date | 30 January 2009 |
| Recommended investment period | Medium to longer term (five years plus) |
| Buy/sell spread | +/-0.20% |
| Entry/exit fees | Nil |
| Management fees and costs ⁴ | 0.89% p.a. of Net Asset Value of the Fund |
| Performance fee | 15% of any amount by which the Fund's return is more than 2% greater than the return generated by the S&P/ASX 300 Accumulation Index |

How to invest

The Fund is open to investors via the PDS (available on our [website](#)), mFund (code: BAE02), or the following platforms.

- AMP (My North)
- BT (Panorama, Asgard (Master Trust, Employee Super, Infinity eWrap)
- CFS (FirstWrap, IX(PIS))
- Dash
- Grow Wrap
- Hub24 (Super, IDPS)
- Macquarie Wrap (IDPS, Super, Accumulator)
- MLC (Navigator, Wrap)
- Mason Stevens
- Morgan Stanley
- Netwealth (Super Service, Wrap Service, IDPS)
- Oasis (Wealthtrac)
- Powerwrap (Smartwrap)

Get in touch



baep.com.au



client.experience@bennelongfunds.com



1800 895 388 (AU) or 0800 442 304 (NZ)

1 S&P/ASX 300 Accumulation Index

2 Inception date is 30 January 2009

3 Calculations are based on net returns (after fees and expenses) and assume the reinvestment of distributions.

4 Management fees and costs consist of annual management fee rate and capped recoverable expenses. For a detailed split of the fees and costs, please refer to the fund(s) PDS.

This information is issued by Bennelong Funds Management Ltd (ABN 39 111 214 085, AFSL 296806) (BFML) in relation to the Bennelong Concentrated Australian Equities Fund. The Fund is managed by Bennelong Australian Equity Partners, a Bennelong boutique. This is general information only, and does not constitute financial, tax or legal advice or an offer or solicitation to subscribe for units in any fund of which BFML is the Trustee or Responsible Entity (Bennelong Fund). This information has been prepared without taking account of your objectives, financial situation or needs. Before acting on the information or deciding whether to acquire or hold a product, you should consider the appropriateness of the information based on your own objectives, financial situation or needs or consult a professional adviser. You should also consider the relevant Information Memorandum (IM) and or Product Disclosure Statement (PDS) which is available on the BFML website, bennelongfunds.com, or by phoning 1800 895 388 (AU) or 0800 442 304 (NZ). Information about the Target Market Determinations (TMDs) for the Bennelong Funds is available on the BFML website. BFML may receive management and or performance fees from the Bennelong Funds, details of which are also set out in the current IM and or PDS. BFML and the Bennelong Funds, their affiliates and associates accept no liability for any inaccurate, incomplete or omitted information of any kind or any losses caused by using this information. All investments carry risks. There can be no assurance that any Bennelong Fund will achieve its targeted rate of return and no guarantee against loss resulting from an investment in any Bennelong Fund. Past fund performance is not indicative of future performance. Information is current as at the date of this document. Bennelong Australian Equity Partners Pty Ltd (ABN 69 131 665 122) is a Corporate Authorised Representative of BFML.